Early therapeutics development with phase II emphasis

Ended Definitive Contract Awarded Last action

Contract number
HHSN261200622006C
Awardee
Awarding agency
Obligated
$6,174,481

Award facts

Opportunity
  • N01CM5701816 Solicitation number
Contract value 12% obligated
  • $34,592,144.75 Current, with exercised options
  • $51,129,580.75 Potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
Not on record
Set-aside
No set-aside
Competition
Full and Open Competition · 11 offers Negotiated Proposal / Quote
Pricing
Cost No Fee
Place of performance
New York, NY 10065, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Change Order 17 -$168,899
Change Order 16 -$31,525
Other Administrative Action 15 $0
Other Administrative Action 14 · Other functions the purpose of this modification is to extend the arra portion of this contract through january 1, 2012. $0
Other Administrative Action 13 $0
Other Administrative Action 12 · The purpose of this modification is to extend the arra portion of this contract through january 1, 2012. $0
Funding Only Action 11 $263,935
Other Administrative Action 10 $113,115
Exercise an Option 9 $346,045
Funding Only Action 8 · Biomedical (basic) $232,060
Funding Only Action 7 · Recovery act - actnow clinical trial 8461 under "early therapeutics development with phase II emphasis" arra::yes::arra $2,227,911
Exercise an Option 6 $620,040
Funding Only Action 5 $417,584
Funding Only Action 4 $289,804
Funding Only Action 3 $274,364
Additional Work (new agreement, FAR part 6 applies) 2 $475,047
Funding Only Action 1 $102,921
Original award $1,012,079
Show all 18

About this award

Written by GovTribe AI ·

This is a federal contract award from the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research organization located in New York City. The $51,129,580.75 cost-reimbursement contract is for early-stage therapeutic development with a focus on Phase II clinical trials. The contract has no set-aside designation and was awarded on January 1, 2006 with a completion date of February 20, 2015. Sloan-Kettering Institute is a world-renowned cancer research organization that has received significant federal funding for advanced cancer research and the development of novel diagnostic and therapeutic technologies. This contract likely supports the institute's ongoing efforts to translate laboratory discoveries into potential clinical interventions for cancer treatment.

Quick answers

Who was awarded contract HHSN261200622006C?

HHSN261200622006C was awarded to Sloan-Kettering Institute For Cancer Research by National Cancer Institute (National Institutes of Health) on January 1, 2006.

How much is contract HHSN261200622006C worth?

The government has obligated $6,174,481 on HHSN261200622006C. Its current value, with exercised options, is $34,592,145. Its potential value, with all options, is $51,129,581.

Was contract HHSN261200622006C competed?

The extent of competition for HHSN261200622006C was full and open competition. The government received 11 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login